Core Insights - The Yttrium-90 microsphere injection, 易甘泰®, has benefited over 3,000 liver cancer patients since its launch in mainland China in 2022, showcasing its significant impact in the treatment of liver tumors [1] - The product received FDA approval for a new indication for unresectable hepatocellular carcinoma (HCC) on July 7, 2025, making it the first and only selective internal radiation therapy product approved for both unresectable HCC and colorectal cancer liver metastases [1][5] - The 15 abstracts related to Yttrium-90 microspheres presented at the 15th Asia-Pacific Primary Liver Cancer Expert Alliance (APPLE) conference highlight its clinical applicability and effectiveness across different stages of HCC [4][2] Group 1: FDA Approval and Clinical Impact - The FDA's early approval was based on the promising mid-term results of the DOORwaY90 clinical trial, which reported an objective response rate of 98.5% and a local tumor control rate of 100% [4][5] - The approval aligns with real-world data from Chinese patients, indicating broad applicability of 易甘泰® in local clinical settings [4] - The product's success is expected to accelerate its commercialization in China and reshape the treatment landscape for liver cancer [1][5] Group 2: Market Context and Future Prospects - According to GLOBOCAN 2022, liver cancer is the sixth most common cancer globally, with approximately 870,000 new cases and 760,000 deaths annually [6] - In China, liver cancer accounted for about 370,000 new cases in 2022, representing 42.5% of global cases, and the mortality rate was approximately 320,000, also the highest globally [6][8] - The Chinese liver cancer drug market is projected to grow at a compound annual growth rate (CAGR) of 12.3%, reaching 45.21 billion yuan by 2030 [8][9] Group 3: Company Development and Innovation - The company has established a comprehensive nuclear medicine industry chain, covering research, production, sales, and regulatory qualifications, with 15 innovative products in the pipeline targeting various cancers [11][17] - The newly launched Chengdu Wenjiang nuclear medicine R&D and production base, with an investment exceeding 3 billion yuan, aims to enhance production capabilities and meet domestic and international demands [17][19] - The base features advanced automation and a full-process radiation monitoring system, positioning the company as a leader in the nuclear medicine sector [18][19]